Blend Therapeutics Appoints Richard Wooster, Ph.D., As Chief Scientific Officer

Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has appointed pharmaceutical industry veteran Richard Wooster, Ph.D., as Chief Scientific Officer. Dr. Wooster will be responsible for leading the Company’s research and development strategy and clinical operations as its lead drug candidates focused on oncology advance toward clinical development.

Help employers find you! Check out all the jobs and post your resume.